ID17768A - Metoda pengobatan - Google Patents

Metoda pengobatan

Info

Publication number
ID17768A
ID17768A IDP971535A ID971535A ID17768A ID 17768 A ID17768 A ID 17768A ID P971535 A IDP971535 A ID P971535A ID 971535 A ID971535 A ID 971535A ID 17768 A ID17768 A ID 17768A
Authority
ID
Indonesia
Prior art keywords
amount
mammal
interferon
treatment method
administered
Prior art date
Application number
IDP971535A
Other languages
English (en)
Inventor
Michael Gerard Tovey
Original Assignee
Pharma Pasific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN9765A external-priority patent/AUPN976596A0/en
Priority claimed from AUPO3959A external-priority patent/AUPO395996A0/en
Priority claimed from AUPO4387A external-priority patent/AUPO438796A0/en
Application filed by Pharma Pasific Pty Ltd filed Critical Pharma Pasific Pty Ltd
Publication of ID17768A publication Critical patent/ID17768A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IDP971535A 1996-05-09 1997-05-09 Metoda pengobatan ID17768A (id)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
AUPO3959A AUPO395996A0 (en) 1996-12-03 1996-12-03 Stimulation of host defence mechanisms
AUPO4387A AUPO438796A0 (en) 1996-12-24 1996-12-24 Method of treatment
US08/853,292 US6361769B1 (en) 1996-05-09 1997-05-09 Stimulation of host defense mechanisms against viral challenges

Publications (1)

Publication Number Publication Date
ID17768A true ID17768A (id) 1998-01-29

Family

ID=27424412

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP971535A ID17768A (id) 1996-05-09 1997-05-09 Metoda pengobatan

Country Status (15)

Country Link
US (1) US6361769B1 (id)
EP (1) EP0906119B1 (id)
JP (1) JP3806445B2 (id)
CN (1) CN1151841C (id)
AT (1) ATE316792T1 (id)
AU (1) AU724689B2 (id)
BR (1) BR9709068A (id)
CA (1) CA2253971A1 (id)
DE (1) DE69735202T2 (id)
ES (1) ES2260791T3 (id)
ID (1) ID17768A (id)
IL (2) IL126971A0 (id)
NZ (1) NZ332689A (id)
TW (1) TW482676B (id)
WO (1) WO1997041884A1 (id)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CN1555264A (zh) 1999-01-08 2004-12-15 3M 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
DE60021760T2 (de) * 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
EP1602378A1 (en) * 1999-12-09 2005-12-07 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6415797B1 (en) * 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
US20050031587A1 (en) * 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
DE60324700D1 (de) * 2002-10-11 2008-12-24 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
US20040136917A1 (en) * 2003-01-06 2004-07-15 Eugene Mandrea Methods of stimulating immune response in virally infected individuals
US20050267144A1 (en) * 2003-01-06 2005-12-01 Eugene Mandrea Methods of stimulating immune response in virally infected individuals
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
EP1757686A4 (en) * 2004-04-09 2008-03-12 Chugai Pharmaceutical Co Ltd INDUCER OF CELL DEATH
JP2008502732A (ja) * 2004-06-12 2008-01-31 ファーマ パシフィック プロプリエタリイ リミテッド ワクチンに対する免疫応答を増強する方法
JP5057967B2 (ja) * 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
AU2006256041B2 (en) * 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
AR061986A1 (es) * 2006-07-13 2008-08-10 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2252323A4 (en) * 2008-02-15 2012-01-11 Hemispherx Biopharma Inc GENETIC REGULATION OF HUMAN DEFENSE MECHANISMS AGAINST SLIPPING EXPOSURE TO NATURAL INTERFERON ALPHA GENES
JP5908397B2 (ja) 2009-06-09 2016-04-26 デフィルス、インコーポレイテッドＤｅｆｙｒｕｓ， Ｉｎｃ． 病原体感染を予防又は治療するためのインターフェロン投与
CN102309758B (zh) * 2010-07-02 2013-02-20 北京凯因科技股份有限公司 一种治疗肠道病毒感染引起的疾病的药物组合物
US20130129678A1 (en) 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000588A1 (en) 1980-08-22 1982-03-04 Illinois Univ Delivery of biologically active components of heterologous species interferon isolates
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
CA2098393A1 (en) * 1990-12-14 1992-06-15 Robert J. Spiegel Oral administration of alpha interferon to treat lung malignancies
EP0578823B1 (en) 1991-04-08 2002-01-23 Sumitomo Pharmaceuticals Company, Limited Porous solid preparation containing physiologically active protein substance
CA2094217A1 (en) 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH06298665A (ja) * 1993-04-14 1994-10-25 Toray Ind Inc 抗ウイルス剤
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type

Also Published As

Publication number Publication date
AU724689B2 (en) 2000-09-28
NZ332689A (en) 2000-07-28
CA2253971A1 (en) 1997-11-13
WO1997041884A1 (en) 1997-11-13
DE69735202D1 (de) 2006-04-13
EP0906119A4 (en) 1999-10-20
EP0906119A1 (en) 1999-04-07
TW482676B (en) 2002-04-11
BR9709068A (pt) 2000-01-11
IL126971A0 (en) 1999-09-22
CN1151841C (zh) 2004-06-02
JP3806445B2 (ja) 2006-08-09
CN1218408A (zh) 1999-06-02
IL126971A (en) 2007-12-03
ES2260791T3 (es) 2006-11-01
EP0906119B1 (en) 2006-02-01
US6361769B1 (en) 2002-03-26
ATE316792T1 (de) 2006-02-15
DE69735202T2 (de) 2006-11-02
JP2000505478A (ja) 2000-05-09
AU2399397A (en) 1997-11-26

Similar Documents

Publication Publication Date Title
ID17768A (id) Metoda pengobatan
PT880350E (pt) Tratamento de esclerose multipla
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ATE181835T1 (de) Wundbehandlung mittels biologisch aktiver peptide
CA2116559A1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
IL113280A0 (en) Method of treating auto-immune diseases using type one interferons
BR9709223A (pt) Estimulação dos mecanismos de defesa do hospedeiro contra tumores.
EP0906108A4 (en) METHOD FOR TREATING HEART FAILURE WITH ENDOTHELINE ANTAGONIST.
TW263437B (id)
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
RU2003100517A (ru) Новый интерферон для лечения рассеянного склероза
SU1097329A1 (ru) Способ лечени беременных с иммунным конфликтом
ECSP972109A (es) Estimulacion de los mecanismos de defensa del huesped contra tumores
ECSP972107A (es) Estimulacion de los mecanismos de defensa del huesped contra estimulaciones virales
MY118982A (en) Method of reducing tissue damage associated with ischemia
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
RU97115829A (ru) Способ лечения коклюша у детей
RU97115801A (ru) Способ лечения стенозирующих ларинготрахеитов у детей
UA15554A (uk) Спосіб прогhозуваhhя ефективhості рефлексотерапії за лазориком